Companies › Salubris Biotherapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Cardiovascular, Oncology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JK07 Anti-HER3 antibody fused with EGF-domain of Neuregulin-1b | ERBB3 | Phase 2 | Heart Failure With Reduced Ejection Fraction | – |
| JK06 Biparatopic anti-5T4 antibody | TPBG | Phase 1 | Solid Tumor | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06369298 | JK07 | Phase 2 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Oct 2026 |
| NCT06667960 | JK06 | Phase 1 | Solid Tumor | Oncology | Apr 2028 |
Aston Sci. Chengdu SciMount Pharmatech SystImmune Beijing Sungen Biomedical Technology MediWound
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.